In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Pluristem (PSTI), with a price target of $3. The company’s shares opened today at $0.86, close to its 52-week low of $0.80.
McCarthy commented:
“On 12/14, Pluristem held an investor event with KOLs (Dr. to discuss their pipeline in peripheral artery disease (PAD): including PLX-PAD in critical limb ischemia (CLI), intermittent claudication (IC) and hip fracture.”
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -6.6% and a 26.4% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pluristem with a $3.25 average price target, implying a 277.9% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $3.50 price target.
.
See today’s analyst top recommended stocks >>
Based on Pluristem’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $8.79 million. In comparison, last year the company had a GAAP net loss of $7.39 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pluristem Therapeutics, Inc. is a biotechnology company, which engages in the provision of cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions.
